Migraine with or Without Aura 1 (MA)

Categories: Genetic diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Migraine with or Without Aura 1

MalaCards integrated aliases for Migraine with or Without Aura 1:

Name: Migraine with or Without Aura 1 57
Migraine 57 11 42 52 75 28 53 5 41 14 63 38 31 33
Migraine with or Without Aura, Susceptibility to, 1 57 28 5
Migraine Disorders 43 71
Migraine Disorder 11 42
Migraine Variant 11 71
Migraines 42 14
Migraine with or Without Aura 11
Headache Including Migraine 53
Migraine, Susceptibility to 5
Headache Migrainous 42
Disorder, Migraine 42
Headache Migraine 42
Migraine Headache 42
Migraine Syndrome 42
Classic Migraine 42
Common Migraine 42
Mgr1 57
Mgau 57
Ma 57



Autosomal dominant 57


57 (Updated 08-Dec-2022)
headache duration 4-72 hours
aggravated by physical activity
genetic heterogeneity, see, e.g., mgr2 , mgr3 , mgr4 , mgr5 , mgr6


External Ids:

Disease Ontology 11 DOID:6364
OMIM® 57 157300
OMIM Phenotypic Series 57 PS157300
ICD9CM 34 346
MeSH 43 D008881
NCIt 49 C89715
SNOMED-CT 68 155046006 193036004
MedGen 40 C3887485
UMLS 71 C0042331 C0149931

Summaries for Migraine with or Without Aura 1

MedlinePlus: 41 What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include: Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often) Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include: Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats Who is at risk for migraines? About 12% of Americans get migraines. They can affect anyone, but you are more likely to have them if you: Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy. What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine.: Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day. Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will: Take your medical history Ask about your symptoms Do a physical and neurological exam An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Migraine with or Without Aura 1, also known as migraine, is related to familial hemiplegic migraine and migraine without aura, and has symptoms including tremor, back pain and headache. An important gene associated with Migraine with or Without Aura 1 is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Type II diabetes mellitus and Cellular roles of Anthrax toxin. The drugs Ketamine and Betamethasone have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and cortex, and related phenotypes are photophobia and vomiting

MedlinePlus Genetics: 42 A migraine is a type of headache that typically causes intense, throbbing pain usually in one area of the head. People can experience migraines once a year to multiple times a week. A person is considered to have chronic migraines if they experience 15 or more headache days a month with eight of those days involving migraine headaches. Migraines typically first start during a person's teens to early twenties, but they can begin anytime from early childhood to late-adulthood.A migraine usually has three stages: the period leading up to the headache (known as the premonitory or prodromal phase), the migraine itself (the headache phase), and the period following the headache (known as the postdromal phase).The premonitory phase can start from several hours up to several days before the headache appears. In this phase, affected individuals can experience extreme tiredness (fatigue), concentration problems, and muscle stiffness in the neck. A wide variety of additional signs and symptoms can occur including excessive yawning, food cravings, irritability, depression, sensitivity to light, and nausea. About one-third of people with migraine experience a temporary pattern of neurological symptoms called an aura. An aura typically develops gradually over a few minutes and lasts between 5 and 60 minutes. Auras commonly include temporary visual changes such as blind spots (scotomas), flashing lights, and zig-zagging lines of color. Additional features of aura can include numbness, difficulty with speech and language, episodes of extreme dizziness (vertigo), and double vision. During an aura, affected individuals might experience abnormal sensations including tingling or numbness, usually of the hands or mouth. An aura usually starts within one hour of the start of a migraine. In some cases, an aura can occur without a subsequent migraine.In the headache phase, the pain may last from a few hours to a few days. Affected individuals tend to experience nausea, vomiting, dizziness, and sensitivity to light and sound in addition to headache. Some have changes in their vision or sensitivity to odors and touch.The postdromal phase usually lasts a few hours but can linger for more than a day. In this phase, the headache pain is gone but individuals can experience fatigue, drowsiness, decreased energy, concentration problems, irritability, nausea, or sensitivity to light. Affected individuals may also have brief episodes of head pain when moving their head.People with migraine, particularly women who have migraine with aura, have an increased risk of a type of stroke that is caused by a lack of blood flow to the brain (ischemic stroke), but this is a rare occurrence.There are many migraine disorders that usually include additional signs and symptoms. For example, familial hemiplegic migraine and sporadic hemiplegic migraine are characterized by migraine with associated temporary weakness that affects one side of the body (hemiparesis). Additionally, cyclic vomiting syndrome is a migraine disorder usually found in children that causes episodes of nausea and vomiting in addition to headaches.

OMIM®: 57 Migraine is the most common type of chronic, episodic headache, as summarized by Featherstone (1985). One locus for migraine with or without aura (MGR1) has been identified on chromosome 4q24. Other loci for migraine have been identified on 6p21.1-p12.2 (MGR3; 607498), 14q21.2-q22.3 (MGR4; 607501), 19p13 (MGR5; 607508), 1q31 (MGR6; 607516), 15q11-q13 (MGR7; 609179), 5q21 (with or without aura, MGR8, 609570; with aura, MGR9, 609670), 17p13 (MGR10; 610208), 18q12 (MGR11; 610209), 10q22-q23 (MGR12; 611706), and the X chromosome (MGR2; 300125). Mutation in the KCNK18 gene (613655) on chromosome 10q25 causes migraine with aura (MGR13; 613656). A subtype of autosomal dominant migraine with aura (MA), familial hemiplegic migraine (FHM; see 141500), is caused by mutation in the CACNA1A gene (601011) on chromosome 19p13 (FHM1; 141500), by mutation in the ATP1A2 gene (182340) on chromosome 1q21 (FHM2; 602481), or by mutation in the SCN1A gene (182389) on chromosome 2q24 (FHM3; 609634). Another locus for FHM has been mapped to chromosome 1q31 (FHM4; see 607516). There is evidence that a polymorphism in the estrogen receptor gene (ESR1; 133430.0005) and a polymorphism in the TNF gene (191160.0004) may confer susceptibility to migraine. A polymorphism in the endothelin receptor type A gene (EDNRA; 131243.0001) may confer resistance to migraine. (157300) (Updated 08-Dec-2022)

NINDS: 52 The pain of a migraine headache is often described as an intense pulsing or throbbing pain in one area of the head. However, it is much more; the International Headache Society diagnoses a migraine by its pain and number of attacks (at least 5, lasting 4-72 hours if untreated), and additional symptoms including nausea and/or vomiting, or sensitivity to both light and sound. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. Roughly one-third of affected individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, anxiety, hormonal changes, bright or flashing lights, lack of food or sleep, and dietary substances.  Migraine in some women may relate to changes in hormones and hormonal levels during their menstrual cycle.  For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine has a genetic cause.

PubMed Health : 63 Migraine: Migraine is not the same as the usual kind of headaches that most people have every now and then. A migraine attack starts suddenly with severe pain on only one side of your head. The pain is much worse than a normal headache and usually accompanied by other symptoms as well. But these headaches are only considered to be migraines if the typical symptoms have occurred at least five times. Migraines can greatly affect everyday life. Some people only get them occasionally, while others are knocked out by migraines on several days every month. Different types of medicine can help you cope with migraines.

Disease Ontology: 11 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing.

Wikipedia: 75 Migraine (UK: /ˈmiːɡreɪn/, US: /ˈmaɪ-/) is a common neurological disorder characterized by recurrent... more...

Related Diseases for Migraine with or Without Aura 1

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine with or Without Aura 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1270)
# Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 33.7 NOTCH3 MGR6 CALCA CACNA1A
2 migraine without aura 33.6 TNF NOTCH3 ESR1 CACNA1A
4 migraine with aura 32.8 NOTCH3 MGR5 MGR1 ESR1 EDNRA CALCA
5 patent foramen ovale 32.2 TAB2 NOTCH3 EDNRA CALCA CACNA1A
6 brain small vessel disease 1 32.1 NOTCH3 CACNA1A
7 cluster headache 32.0 CALCA CACNA1A
8 trigeminal neuralgia 31.3 ESR1 CALCA CACNA1A
9 cerebral palsy 30.6 TNF CLCN1 CACNA1A BRCA2
10 interval angle-closure glaucoma 30.4 ESR1 CALCA
11 hypertrophy of breast 30.1 ESR1 BRCA2
12 barre-lieou syndrome 30.1 ESR1 CALCA
13 sporadic hemiplegic migraine 11.7
14 migraine, familial hemiplegic, 3 11.7
15 migraine, familial hemiplegic, 1 11.6
16 migraine, familial hemiplegic, 2 11.6
17 migraine with brainstem aura 11.6
18 migraine with or without aura 13 11.6
19 cyclic vomiting syndrome 11.4
20 retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome 11.4
21 familiar or sporadic hemiplegic migraine 11.3
22 familial or sporadic hemiplegic migraine 11.3
23 epilepsy, familial temporal lobe, 4 11.3
24 migraine with or without aura 8 11.3
25 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.2
26 migraine with or without aura 12 11.2
27 vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations 11.2
28 migraine with aura 7 11.2
29 migraine with or without aura 2 11.2
30 episodic ataxia 11.2
31 migraine with or without aura 6 11.1
32 migraine without aura 4 11.1
33 migraine with or without aura 10 11.1
34 migraine with or without aura 3 11.1
35 migraine with aura 9 11.1
36 migraine with or without aura 11 11.1
37 visual snow syndrome 11.0
38 hemicrania continua 11.0
39 sturge-weber syndrome 11.0
40 advanced sleep phase syndrome 11.0
41 alternating hemiplegia of childhood 1 11.0
42 stormorken syndrome 11.0
43 carotidynia 11.0
44 migraine with or without aura 5 11.0
45 dystonia 9 11.0
46 alpha-methylacyl-coa racemase deficiency 11.0
47 peroxisome biogenesis disorder 14b 11.0
48 familial porencephaly 11.0
49 episodic ataxia, type 2 10.9
50 orthostatic intolerance 10.9

Comorbidity relations with Migraine with or Without Aura 1 via Phenotypic Disease Network (PDN):

Anxiety Esophagitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with or Without Aura 1:

Diseases related to Migraine with or Without Aura 1

Symptoms & Phenotypes for Migraine with or Without Aura 1

Human phenotypes related to Migraine with or Without Aura 1:

30 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 30 HP:0000613
2 vomiting 30 HP:0002013
3 phonophobia 30 HP:0002183
4 nausea 30 HP:0002018
5 migraine with aura 30 HP:0002077
6 migraine without aura 30 HP:0002083

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neurologic Central Nervous System:
migraine with aura
migraine without aura
headache is unilateral
Abdomen Gastrointestinal:

Clinical features from OMIM®:

157300 (Updated 08-Dec-2022)

UMLS symptoms related to Migraine with or Without Aura 1:

tremor; back pain; headache; syncope; hemiplegia; pain; nausea; recurrent paroxysmal headache; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness; scotoma, scintillating; hemicrania

MGI Mouse Phenotypes related to Migraine with or Without Aura 1:

# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.28 BRCA2 CACNA1A CALCA CLCN1 EDNRA ESR1

Drugs & Therapeutics for Migraine with or Without Aura 1

PubMed Health treatment related to Migraine with or Without Aura 1: 63

A lot of people who have migraines know from experience what helps them. This often involves lying down in a quiet and dark room and putting cool wet towels or cooling pads on the side of their head that hurts. Most people take medicine to get through attacks that are especially painful. Medications used for migraine attacks include, in particular, acetaminophen (paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid (the drug in medicines like Aspirin ), diclofenac or ibuprofen , as well as special migraine medications like triptans. Acetaminophen (paracetamol), acetylsalicylic acid and ibuprofen are available without a prescription, as are two of the triptan drugs. But before using medication yourself it’s a good idea to see a doctor to find out if the headaches are actually migraines . Using painkillers and migraine medication too often can itself make the headaches worse. For this reason, people are advised not to take painkillers and migraine medications on more than ten days per month.

Drugs for Migraine with or Without Aura 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 461)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
Eletriptan Approved, Investigational Phase 4 143322-58-1 77993
Ergotamine Approved Phase 4 113-15-5 8223
Dihydroergotamine Approved, Investigational Phase 4 6190-39-2, 511-12-6 10531
Almotriptan Approved, Investigational Phase 4 181183-52-8, 154323-57-6 123606
Norepinephrine Approved Phase 4 51-41-2 439260
Ethinylestradiol Approved Phase 4 57-63-6 5991
Ticagrelor Approved Phase 4 274693-27-5 9871419
Venlafaxine Approved Phase 4 99300-78-4, 93413-69-5 5656
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
Nadolol Approved Phase 4 42200-33-9 39147
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Dinoprostone Approved Phase 4 363-24-6, 7448-03-5 5280360
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
Ferrous fumarate Approved Phase 4 141-01-5
Norethisterone Approved Phase 4 68-22-4 199472 6230
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
Idebenone Approved, Investigational Phase 4 58186-27-9 3686
Flunarizine Approved Phase 4 52468-60-7 941361
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
Donepezil Approved Phase 4 120014-06-4 3152
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868

Interventional clinical trials:

(show top 50) (show all 1236)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Registry for Migraine - Clinical Core Unknown status NCT04603976 Phase 4 Erenumab
3 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
4 Comparison of the Effect of Intravenous Paracetamol, Dexketoprofen and Ibuprofen on Visual Analogue Scale (VAS) in the Treatment of Acute Migraine Attack Headache in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial Unknown status NCT04372264 Phase 4 Paracetamol;Dexketoprofen;Ibuprofen
5 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
6 Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine Unknown status NCT02307071 Phase 4
7 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
8 Ketamine v. Ketorolac for Management of Generalized Tension Type Headache Unknown status NCT03221569 Phase 4 Intravenous ketamine;Ketorolac;Normal saline
9 Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines Unknown status NCT00363506 Phase 4
10 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo
11 Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax Completed NCT00259649 Phase 4 eletriptan
12 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
13 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
14 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
15 An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy Completed NCT00632385 Phase 4 Eletriptan
16 AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain Completed NCT00212823 Phase 4 almotriptan malate
17 AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache Completed NCT00210509 Phase 4 almotriptan malate
18 A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
19 Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study) Completed NCT01807234 Phase 4 Ketorolac;Sumatriptan;Placebo
20 Ticagrelor Therapy for RefrACTORy Migraine Study Pilot (TRACTOR) Completed NCT02518464 Phase 4 Ticagrelor 90 mg twice per day
21 A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine Completed NCT04017741 Phase 4 Combined Depo-Medrone and Lidocaine;Sodium Chloride 0.9% Inj
22 Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase. Completed NCT03689361 Phase 4
23 A Randomized-controlled Study; Comparison of the Effectiveness of Intravenous Ibuprofen and Intravenous Dexketoprofen in the Treatment of Migraine-related Headache in the Emergency Department Completed NCT04533568 Phase 4 Ibuprofen 400 mg;Dexketoprofen
24 Imaging the Migraine Brain Pre- and Post-Erenumab: an MRI Study to Identify Functional and Structural Changes That Correlate With Patient Improvement Completed NCT03773562 Phase 4 Erenumab
25 Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study Completed NCT01709708 Phase 4 Marcaine;Saline
26 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine Completed NCT02147561 Phase 4
27 Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis Completed NCT02639598 Phase 4 Flunarizine;Topiramate
28 A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine Completed NCT00846495 Phase 4 topiramate;frovatriptan
29 A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated. Completed NCT00637286 Phase 4 Zolmitriptan
30 A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist Completed NCT04294147 Phase 4 Galcanezumab;Erenumab
31 A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years) Completed NCT02287376 Phase 4 Diclofenac Potassium for Oral Solution
32 Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. A Randomized, Double-blind Trial. Completed NCT03698409 Phase 4 Preserved saline in reconstitution of Botox
33 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Completed NCT00719134 Phase 4 Maxalt;placebo pill;placebo pills
34 Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study Completed NCT01695317 Phase 4 Acetyl-L-carnitine
35 Exploratory Study of the Natural History, Clinical Outcomes, and Neuronal Endplate Changes in Subjects Reporting Short Duration vs. Long Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Completed NCT02037425 Phase 4 onabotulinumtoxinA
36 Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®) Completed NCT01833130 Phase 4 Normal saline (placebo)
37 A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients Completed NCT03927144 Phase 4 AMG334;Oral Prophylactic
38 A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS Completed NCT00634985 Phase 4 eletriptan
39 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
40 Head-to-head Study of Erenumab Against topiRamate-a Double-blind, Double Dummy Migraine Study to Assess Tolerability and Efficacy in a patiEnt -Centered Setting Completed NCT03828539 Phase 4 Topiramate;Topiramate matching placebo
41 Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study) Completed NCT00799045 Phase 4 Clopidogrel
42 Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults Completed NCT00792636 Phase 4 sumatriptan and naproxen sodium combination tablet;sumatriptan tablet;naproxen sodium tablet
43 To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study. Completed NCT02035111 Phase 4 Tianshu capsule;Sugar pill
44 A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine Completed NCT00443352 Phase 4 duloxetine
45 An Observer-Blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine Completed NCT00397254 Phase 4 rizatriptan
46 Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study Completed NCT02389829 Phase 4 Hydromorphone;Prochlorperazine;Diphenhydramine
47 Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine Over 3 Years of Treatment. A Completed NCT03606356 Phase 4 Onabotulinum toxin A
48 Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine Completed NCT01071096 Phase 4 OnabotulinumtoxinA;Saline
49 Effectivity of Propranolol and Venlafaxine in Treatment of Vestibular Migraine: A Randomized Controlled Clinical Trial Completed NCT02350985 Phase 4 Propranolol;Venlafaxine
50 Drug and Non-Drug Treatment of Severe Migraine Completed NCT00910689 Phase 4 Propranolol or nadolol;Placebo control;Optimal Acute Therapy

Search NIH Clinical Center for Migraine with or Without Aura 1

Cochrane evidence based reviews: migraine disorders

Genetic Tests for Migraine with or Without Aura 1

Genetic tests related to Migraine with or Without Aura 1:

# Genetic test Affiliating Genes
1 Migraine 28
2 Migraine with or Without Aura, Susceptibility to, 1 28 EDNRA ESR1 TNF

Anatomical Context for Migraine with or Without Aura 1

Organs/tissues related to Migraine with or Without Aura 1:

MalaCards : Brain, Pituitary, Cortex, Eye, Prefrontal Cortex, Spinal Cord, Trigeminal Ganglion

Publications for Migraine with or Without Aura 1

Articles related to Migraine with or Without Aura 1:

(show top 50) (show all 31994)
# Title Authors PMID Year
MTHFR T677 homozygosis influences the presence of aura in migraineurs. 53 62 57
15154859 2004
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. 53 62 57
15014183 2004
CGRP may play a causative role in migraine. 53 62 57
11993614 2002
The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. 53 62 57
11121176 2000
Genome-wide meta-analysis identifies new susceptibility loci for migraine. 62 57
23793025 2013
Spreading depression triggers headache by activating neuronal Panx1 channels. 62 57
23449592 2013
Shared genetic factors in migraine and depression: evidence from a genetic isolate. 62 57
20071666 2010
Trait components provide tools to dissect the genetic susceptibility of migraine. 62 57
16773568 2006
Migraine and MTHFR C677T genotype in a population-based sample. 62 57
16365871 2006
Familial risk of migraine: variation by proband age at onset and headache severity. 62 57
16476932 2006
Migraine with aura is a risk factor for unprovoked seizures in children. 62 57
16374824 2006
The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. 62 5
15133719 2004
Localization of a gene for migraine without aura to chromosome 4q21. 62 57
14513409 2003
Nuclear factor-kappaB as a molecular target for migraine therapy. 62 57
11921057 2002
A susceptibility locus for migraine with aura, on chromosome 4q24. 62 57
11836652 2002
Migraine without aura: a population-based twin study. 62 57
10514097 1999
Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. 62 57
9989627 1999
Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. 62 57
9259375 1997
Variation in migraine prevalence by race. 62 57
8710124 1996
Inheritance of migraine investigated by complex segregation analysis. 62 57
8522335 1995
Familial occurrence of migraine without aura and migraine with aura. 62 57
8392151 1993
Familial migraine in a Mexican population. 62 57
1608495 1992
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. 62 57
1727198 1992
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. 62 57
1699472 1990
Segregation analysis of migraine in 128 families. 62 57
3527442 1986
Migraine and muscle contraction headaches: a continuum. 62 57
4019180 1985
Biochemical predisposition to dietary migraine: the role of phenolsulphotransferase. 62 57
6343297 1983
Migraine in twins. 62 57
859128 1977
14322314 1965
Familiar occurrence of migraine headache: a study of heredity. 62 57
13196752 1954
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. 62 41
36460983 2022
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. 62 41
36404301 2022
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors. 57
2940961 1986
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. 41
36380284 2022
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 53 62
20518725 2010
Dopamine: what's new in migraine? 53 62
20164768 2010
What have we learnt from triggering migraine? 53 62
20173638 2010
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 53 62
19936882 2010
CGRP receptor antagonism and migraine. 53 62
20430315 2010
The PACAP receptor: a novel target for migraine treatment. 53 62
20430318 2010
Migraine and obesity: epidemiology, mechanisms, and implications. 53 62
19845784 2010
Calcitonin gene-related peptide: A molecular link between obesity and migraine? 53 62
20369076 2010
Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. 53 62
20188075 2010
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. 53 62
20368903 2010
Single nucleotide polymorphisms of the serotonin transporter gene in migraine--an association study. 53 62
19845785 2010
Migraine models. 53 62
20336417 2010
Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. 53 62
19607849 2010
A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. 53 62
20080591 2010
CGRP antagonists: hope for a new era in acute migraine treatment. 53 62
20120204 2009

Variations for Migraine with or Without Aura 1

ClinVar genetic disease variations for Migraine with or Without Aura 1:

5 (show all 19)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter) SNV Pathogenic
523355 rs148292941 GRCh37: 1:161140885-161140885
GRCh38: 1:161171095-161171095
2 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic
812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
3 CAPN3 NM_000070.3(CAPN3):c.1746-20C>G SNV Pathogenic
92408 rs201892814 GRCh37: 15:42695919-42695919
GRCh38: 15:42403721-42403721
4 CAPN3 NM_000070.3(CAPN3):c.550del (p.Thr184fs) DEL Pathogenic
17621 rs80338800 GRCh37: 15:42680001-42680001
GRCh38: 15:42387803-42387803
5 BRCA2 NM_000059.4(BRCA2):c.4936_4939del (p.Glu1646fs) DEL Pathogenic
37935 rs80359473 GRCh37: 13:32913425-32913428
GRCh38: 13:32339288-32339291
6 CLCN1 NM_000083.3(CLCN1):c.950G>A (p.Arg317Gln) SNV Likely Pathogenic
17542 rs80356702 GRCh37: 7:143027961-143027961
GRCh38: 7:143330868-143330868
7 TAB2 NM_001292034.3(TAB2):c.1039C>T (p.Arg347Ter) SNV Likely Pathogenic
373443 rs1057518422 GRCh37: 6:149700090-149700090
GRCh38: 6:149378954-149378954
8 CACNA1A NM_001127222.2(CACNA1A):c.4174G>A (p.Val1392Met) SNV Likely Pathogenic
195935 rs794727411 GRCh37: 19:13372340-13372340
GRCh38: 19:13261526-13261526
9 NOTCH3 NM_000435.3(NOTCH3):c.1450T>G (p.Cys484Gly) SNV Likely Pathogenic
523370 rs1555728965 GRCh37: 19:15299088-15299088
GRCh38: 19:15188277-15188277
10 ESR1 NM_000125.4(ESR1):c.1782G>A (p.Thr594=) SNV Risk Factor
1263746 GRCh37: 6:152420095-152420095
GRCh38: 6:152098960-152098960
11 SLC2A1 NM_006516.4(SLC2A1):c.1407G>C (p.Gln469His) SNV Uncertain Significance
374095 rs201748668 GRCh37: 1:43392784-43392784
GRCh38: 1:42927113-42927113
12 AHNAK2 NM_138420.4(AHNAK2):c.6406_6408delinsGAC (p.Gln2136Asp) INDEL Uncertain Significance
983126 rs1898490907 GRCh37: 14:105415380-105415382
GRCh38: 14:104949043-104949045
13 TNF NM_000594.4(TNF):c.17T>A (p.Met6Lys) SNV Uncertain Significance
1697317 GRCh37: 6:31543535-31543535
GRCh38: 6:31575758-31575758
14 MAP2K2 NM_030662.4(MAP2K2):c.514A>G (p.Lys172Glu) SNV Uncertain Significance
523536 rs1413580671 GRCh37: 19:4102388-4102388
GRCh38: 19:4102390-4102390
15 STIM1 NM_001382567.1(STIM1):c.1627T>A (p.Ser543Thr) SNV Uncertain Significance
523431 rs1554971682 GRCh37: 11:4107766-4107766
GRCh38: 11:4086536-4086536
16 MYH6 NM_002471.4(MYH6):c.3195G>C (p.Gln1065His) SNV Uncertain Significance
14149 rs267606904 GRCh37: 14:23862177-23862177
GRCh38: 14:23392968-23392968
17 DSP NM_004415.4(DSP):c.5218G>A (p.Glu1740Lys) SNV Uncertain Significance
44926 rs142885240 GRCh37: 6:7581641-7581641
GRCh38: 6:7581408-7581408
18 MYH6 NM_002471.4(MYH6):c.4594C>T (p.Arg1532Cys) SNV Uncertain Significance
239175 rs201827489 GRCh37: 14:23856794-23856794
GRCh38: 14:23387585-23387585
19 SCN5A NM_000335.5(SCN5A):c.892G>A (p.Gly298Ser) SNV Uncertain Significance
9387 rs137854608 GRCh37: 3:38651267-38651267
GRCh38: 3:38609776-38609776

Copy number variations for Migraine with or Without Aura 1 from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 39736 10 118956999 118969809 Copy number KCNK18 Migraine

Expression for Migraine with or Without Aura 1

Search GEO for disease gene expression data for Migraine with or Without Aura 1.

Pathways for Migraine with or Without Aura 1

Pathways related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.3 TNF CACNA1A
2 9.9 TNF ESR1

GO Terms for Migraine with or Without Aura 1

Biological processes related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 ESR1 EDNRA CALCA CACNA1A
2 regulation of biological quality GO:0065008 9.16 TNF EDNRA
3 negative regulation of miRNA maturation GO:1903799 8.62 TNF ESR1

Sources for Migraine with or Without Aura 1

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....